BRAF and melanoma: A combination of a BRAF and PI3K inhibitor effectively eliminates BRAF inhibitor-resistant melanoma cell line clones (Greger et al, 2012; Vredeveld et al, 2012); currently, a clinical trial using vemurafenib and BKM120, a PI3K inhibitor, is ongoing (ClinicalTrials.gov).